Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2016 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results

REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the second quarter ended June...
August 09, 2016 13:53 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim...
August 08, 2016 08:37 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis

REDWOOD CITY, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab...
July 25, 2016 11:00 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th

REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2016 financial results will be released on August 9,...
July 11, 2016 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study

REDWOOD CITY, Calif., July 11, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), a leading global biosimilars company with late-stage clinical products, today reported topline...
June 28, 2016 09:00 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis

Six Month Study Demonstrates Significant Reduction in Contrast-Enhancing Lesions Meeting Primary Endpoint Safety and Tolerability Support Differentiated Product Profile REDWOOD CITY, Calif., June ...
June 13, 2016 14:04 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Provides Update on IPRs

REDWOOD CITY, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced...
June 10, 2016 12:05 ET | Source: Coherus BioSciences, Inc.

Coherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept

REDWOOD CITY, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced...
June 03, 2016 09:00 ET | Source: Coherus Oncology

Coherus BioSciences to Present at Jefferies 2016 Healthcare Conference on June 8

REDWOOD CITY, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today...
May 26, 2016 14:51 ET | Source: Coherus Oncology

Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access

REDWOOD CITY, Calif., May 26, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced...